An apheresis machine separates the blood components from the blood directed to the machine from the patient/donor's veins through tubing. Apheresis can be used for the treatment of various diseases such as familial hypercholesterolemia, Goodpasture's syndrome, hyperviscosity syndrome, myasthenia gravis, the HELLP syndrome of pregnancy, Waldenstrom's macroglobulinemia, clogging of blood vessels (leukostasis) cause by severely elevated white blood count in leukemia, and severely elevated platelet counts in leukemia or myeloproliferative disorders.
The global apheresis equipment market is estimated to account for US$ 2,866.4 Mn in terms of value in 2020 and is expected to reach US$ 6,081.8 Mn by the end of 2027.
Global Apheresis Equipment Market: Drivers
Increasing prevalence of COVID-19 is expected to propel growth of the global apheresis equipment market over the forecast period. For instance, according to a statement by World Apheresis Association in April 2020, apheresis therapy can be widely beneficial in the treatment of patients with the novel coronavirus.
Global Apheresis Equipment Market: Opportunities
Lipoprotein apheresis is effective in the treatment of homozygous familial hypercholesterolemia. However, the therapy is expensive and available in only a few countries. Therefore, reduction in the cost of lipoprotein apheresis and widespread availability of the therapy is expected to offer lucrative growth opportunities for the market players.
Global Apheresis Equipment Market: Restraints
Lack of trained professionals, especially in emerging economies is expected to limit growth of the market. Hiring skilled staff for both therapeutic and donor apheresis is a major challenge faced in both developed and emerging markets. The staff required for apheresis comprises of a practicing doctor and a specialized nurse. Apheresis procedures are often termed to be labor intensive since they require the staff to be present and vigilant during the entire procedure. The skill requirement criteria in the practice of apheresis are also different compared to conventional therapeutic areas.
Plasmapheresis segment was valued at US$ 1,303.7 Mn in 2019 and is forecast to reach a value of US$ 2,735.9 Mn by 2027 at a CAGR of 9.7% between 2020 and 2027. Frequent and increasing use of plasmapheresis is expected to support growth of the segment over the forecast period.
Neurological disorders segment held dominant position in the global apheresis equipment market in 2019, accounting for 52.6% share in terms of value, followed by hematological disorders and renal disorders, respectively. Increasing prevalence of neurological disorders is expected to support growth of the segment over the forecast period.
Increasing clinical trials for cystinosis, a rare genetic, metabolic, lysosomal storage disease caused by mutations in the CTNS gene on chromosome 17p13, is expected to boost adoption of apheresis, thereby boosting growth of the market. For instance, in March 2020, AVROBIO, Inc., a clinical-stage gene therapy company, announced that a second patient in the AVR-RD-04 Phase 1/2 clinical trial in cystinosis has been enrolled and has completed apheresis.
However, several pharmaceutical companies have suspended screening, enrollment and apheresis in clinical studies. For instance, in March 2020, Bristol-Myers Squibb disclosed that the company has temporarily suspended screening, enrollment and apheresis in its cellular therapy clinical studies.
Global Apheresis Equipment Market: Competitive Landscape
Major players operating in the global apheresis equipment market include, Asahi Kasei Medical Co., Ltd., Terumo BCT, Inc., Fenwal, Inc., Haemonetics Corp., Therakos, Inc., B. Braun Melsungen AG, and HemaCare Corporation.
Global Apheresis Equipment Market: Key Developments
April 2019: Asahi Kasei Bioprocess America, a subsidiary of Asahi Kasei Medical Co., Ltd. started Massachusetts Training Center, for customer training and product collaborations in virus filtration, bioprocess and fluid management
February 2019: Terumo BCT started a new regional office in Nairobi to expand its presence in sub-Saharan Africa